Tag Archives: biotech industry

Plexxikon Inc. reports positive clinical data from a Phase 1 extension study of PLX4032 (RG7204) in metastatic melanoma patients. PLX4032 targets the BRAFV600E mutation that occurs in about 50 percent of melanomas and about eight percent of solid tumors. Tumor shrinkage has been observed in nearly all of the currently evaluable patients in the extension study, reflecting a 70 percent response rate. Plexxikon and Roche are co-developing PLX4032 under their 2006 license and collaboration agreement. Read More >

Peptimmune, Inc. has formed a collaboration with the Walter Reed Army Institute of Research and Naval Medical Research Center for the development of Dengue vaccines and point-of-care diagnostics. The goal of the R&D project is to evaluate the company’s Directed Expansion of Epitope Permutations (DEEP) technology to potentially design DENV-specific peptide copolymers. The results of this effort have the potential to provide insights into dengue immunity and advance the development of a protective vaccine. Read Read More >

Dendreon Corporation (Nasdaq: DNDN) today reported regulatory and commercialization progress for PROVENGE® (sipuleucel-T), the company’s investigational prostate cancer product. Dendreon expects to prepare for commercialization of PROVENGE by the middle of next year. Dendreon further plans to initiate a clinical trial of NEUVENGE™ (lapuleucel-T) to treat bladder cancer, and potentially, breast and colorectal cancers. At today’s analyst event, the company also reported the expansion of its manufacturing facility in New Jersey and the addition of Read More >

Dr. J. Joseph Kim, CEO of Inovio Biomedical Corporation (NYSE Amex: INO), presented keynote remarks on universal DNA vaccines to prevent and treat infectious diseases (such as Influenza) at MIT’s Emerging Technologies Conference. Dr. Kim’s speech focused on the advantages of DNA vaccines versus traditional therapies, which includes speed of development, ease of manufacture, and broader immune responses, as well as the “designer” nature of Inovio’s vaccine approach. The conference took place this week in Read More >

XOMA Ltd. (Nasdaq:XOMA) is developing an antibody that has been shown by Dana-Farber Cancer Institute and Harvard Medical School researchers to neutralize group 1 influenza A viruses, including H1N1 and H5N1. XOMA will conduct the program under a $2.2 million subcontract with SRI International of Menlo Park, California. The National Institute of Allergy and Infectious Diseases will fund the subcontract. Read the release.